Manickam Rangaraju
Overview
Explore the profile of Manickam Rangaraju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hammond S, Rangaraju M, Sumner M, Timmler B, Chandrasekar P, Avery R
Open Forum Infect Dis
. 2024 Mar;
11(3):ofae046.
PMID: 38444818
Background: Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection is an uncommon problem typically seen in immunocompromised hosts. Systemic treatment options are limited. The performance of foscarnet and its toxicities in...
2.
Birkmann A, Bonsmann S, Kropeit D, Pfaff T, Rangaraju M, Sumner M, et al.
J Med Chem
. 2022 Oct;
65(20):13614-13628.
PMID: 36202389
When the nucleoside analogue acyclovir was introduced in the early 1980s, it presented a game-changing treatment modality for herpes simplex virus infections. Since then, work has been ongoing to improve...
3.
Merdjan H, Rangaraju M, Tarral A
Clin Drug Investig
. 2015 Mar;
35(5):307-17.
PMID: 25813217
Background And Objective: Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some class D β-lactamases that is currently in clinical development in combination with...
4.
Fogarty C, de Wet R, Mandell L, Chang J, Rangaraju M, Nusrat R
Chest
. 2005 Oct;
128(4):1980-8.
PMID: 16236845
Study Objectives: To demonstrate equivalence in the clinical efficacy of telithromycin vs clarithromycin treatment of outpatients with acute exacerbations of chronic bronchitis (AECB), and to compare the tolerability and respiratory-related...
5.
van Rensburg D, Fogarty C, De Salvo M, Rangaraju M, Nusrat R
J Infect
. 2005 Oct;
51(3):201-5.
PMID: 16230216
The efficacy of oral telithromycin 800mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by Streptococcus pneumoniae resistant to penicillin...
6.
Fogarty C, Buchanan P, Aubier M, Baz M, van Rensburg D, Rangaraju M, et al.
Int J Infect Dis
. 2005 Sep;
10(2):136-47.
PMID: 16183318
Objectives: A pooled analysis of 14 Phase III studies was performed to establish the clinical and bacteriologic efficacy of telithromycin 800 mg once daily in the treatment of pneumococcal community-acquired...
7.
Low D, Felmingham D, Brown S, Rangaraju M, Nusrat R
J Infect
. 2004 Jul;
49(2):115-25.
PMID: 15236918
Objectives: To investigate the correlation between in vitro susceptibility of isolates and clinical outcomes with telithromycin in respiratory tract infections. Methods: The activity of telithromycin was determined by in vitro...